Diabetic Macular Edema Market to Observe Stupendous Growth During the Forecast Period | Adverum Biotechnologies, Allergan (AbbVie, Molecular Partners, Allergo Opthalmics/ Bausch Health, Clearside Biomedical, Graybug Vision, KalVista Pharmaceuticals, Kodia

The Diabetic Macular Edema (DME) Market size in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the UK and Japan) was found to be ~USD 2.9 billion in 2021.
The Diabetic Macular Edema Market is anticipated to grow in the coming years owing to the growing awareness, improved management, and better outcomes with emerging therapies. Moreover, the increase in the diabetic population, a rise in the number of healthcare expenditures, and lifestyle changes are also anticipated to stimulate market growth in the coming years.
DelveInsight's "Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Macular Edema market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Diabetic Macular Edema market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is a complication triggered by diabetic retinopathy (DR), a well-documented consequence of diabetes. DR stands as the most prevalent diabetic eye ailment, contributing significantly to irreversible blindness among individuals in their prime working years across both developed and developing nations.

Typical indications of DR and DME encompass dark spots resembling smudges on glasses, vision gaps, blurred vision, double vision, diminished color perception, and heightened sensitivity to bright light or glare.

Individuals with either Type 1 or Type 2 diabetes face the risk of developing DR and DME. This risk escalates with the duration of diabetes. According to the American Academy of Ophthalmology (AAO), nearly 80% of Type 1 diabetes patients are expected to develop DR within 15 years of diagnosis, while there's a 50% likelihood for Type 2 diabetes patients within approximately 20 years of diagnosis.

Diabetic Macular Edema Market Key Facts
In the 7MM, the total treated cases of Diabetic Macular Edema in first-line were nearly 440,000+ cases in 2021. As per the analysis, these cases are expected to reach 520,000+ by 2034.
In 2021, the total prevalent cases of Diabetic Macular Edema were the highest in the US, with more than 1 million cases, and lowest in France, with 60,000+ cases.
Among EU4 and the UK, Germany had the highest number of prevalent cases of Diabetic Macular Edema (approximately 220,000+ cases) in 2021.
Germany accounted for 100,000+ diagnosed prevalent cases in 2021, which is expected to increase to approximately 103,500+ cases by the year 2034.
The market size is expected to increase during the forecast period (2020‒2034), owing to the launch of upcoming therapies. The United States is the largest market, with an estimated size of around USD 1.7 billion in 2021.
Among the studied geographies, the US accounted for ~60% of the overall market size of Diabetic Macular Edema in 2021.
In January 2022, the United States Food and Drug Administration (US FDA) approved Roche's VABYSMO for treating Diabetic Macular Edema and neovascular (wet) age-related macular degeneration.
In June 2022, Novartis announced the approval of BEOVU (brolucizumab) for the treatment of Diabetic Macular Edema.
Diabetic Macular Edema Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Macular Edema market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Diabetic Macular Edema market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Diabetic Macular Edema Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Diabetic Macular Edema (DME) Epidemiology, Segmented by -
Total Prevalent Cases of Diabetic Macular Edema in the 7MM (2020-2034)
Gender-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM (2020-2034)
Total Diagnosed Cases of Diabetic Macular Edema in the 7MM (2020-2034)
Age-Specific Diagnosed Cases of Diabetic Macular Edema in the 7MM (2020-2034)
Treated cases of Diabetic Macular Edema in the 7MM (2020-2034)
Subgroup-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM (2020-2034)
Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Macular Edema market or expected to be launched during the study period. The analysis covers the Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Macular Edema pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Diabetic Macular Edema Market Will Evolve and Grow by 2034 @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market
Diabetic Macular Edema Therapeutics Analysis
The Leading Companies in the Diabetic Macular Edema Therapeutic Market Include:
Adverum Biotechnologies
Graybug Vision
Roche
Novartis
KalVista Pharmaceuticals
Ocuphire Pharma
Oxurion
YD Life Science
Novartis
Allergan (AbbVie)
Molecular Partners
Allergo Opthalmics/ Bausch Health
Kodiak Sciences
Clearside Biomedical
And Many Others
Diabetic Macular Edema Therapies Covered in the Report Include:
Faricimab: Roche
KSI-301: Kodiak Sciences
ADVM022: Adverum Biotechnologies
APX3330: Ocuphire Pharma
THR-149: Oxurion
UBX1325: Unity Biotechnology
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Diabetic Macular Edema Competitive Intelligence Analysis
4. Diabetic Macular Edema Market Overview at a Glance
5. Diabetic Macular Edema Disease Background and Overview
6. Diabetic Macular Edema Patient Journey
7. Diabetic Macular Edema Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Diabetic Macular Edema Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic Macular Edema Unmet Needs
10. Key Endpoints of Diabetic Macular Edema Treatment
11. Diabetic Macular Edema Marketed Products
12. Diabetic Macular Edema Emerging Drugs and Latest Therapeutic Advances
13. Diabetic Macular Edema Seven Major Market Analysis
14. Attribute Analysis
15. Diabetic Macular Edema Market Outlook (In US, EU5, and Japan)
16. Diabetic Macular Edema Access and Reimbursement Overview
17. KOL Views on the Diabetic Macular Edema Market
18. Diabetic Macular Edema Market Drivers
19. Diabetic Macular Edema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Other Trending Healthcare Reports By DelveInsight
Diabetic Macular Edema (DME) Pipeline Insight
The "Diabetic Macular Edema (DME) Pipeline Insights, 2023" report by DelveInsight, outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema (DME) market.

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.